Mr. Silverman is the former CEO of mtm laboratories AG, an in-vitro diagnostics company which developed and commercialized a portfolio of products using its patent protected biomarkers for early detection and diagnosis of cervical cancer. He was instrumental in building this company into a global, fully integrated business, with a strong foundation of significant clinical utility and commercial momentum. Mr. Silverman successfully negotiated the purchase of mtm by Roche Diagnostics in August 2011 for a total deal value of $270 Million and then facilitated the integration of mtm into Roche.
Prior to mtm laboratories, Mr. Silverman was the Senior Vice-President of Worldwide Commercial Operations for Viacell, a company focused on developing stem cell therapies and cord blood banking. Before this, he spent 6 years with Cytyc Corporation. During his tenure at Cytyc, he served as the Vice President of Marketing and the Vice President of International, and was integral in launching and establishing the core technology (the ThinPrep Pap Test) into the standard of care for cervical cancer screening. Previous positions include Vice-President of Marketing for Pasteur Merieux Connaught, Director of New Product Development for Abbott Laboratories Pharmaceutical Products Division and Management Consultant with Bain and Company.
He earned his Master’s degree in Marketing and Finance from Northwestern’s Kellogg Graduate School of Management and received his Bachelor of Science degree in Pharmacy from the University of Michigan. Mr. Silverman currently works with several companies in a Board and Advisory capacity.
Dr. Matthew (Matt) Gevaert is Chief Executive Officer of KIYATEC Inc., a life sciences company commercializing advanced three-dimensional (3D) cell culture plasticware and cell-based diagnostics. Possessing a background which combines both business and technology, he led the commercialization of Clemson University’s biomedical and biotechnology intellectual property portfolio for nearly 5 years, working with both entrepreneurial start-ups and large, industry leading corporations. Currently Matt serves as president of SCMedTech, the industry organization for South Carolina’s medical device and technology companies.
Gevaert grew up in Ontario, Canada and graduated from the University of Waterloo with a bachelor’s degree in Applied Chemistry. He also holds a master’s degree and a doctorate in Bioengineering from Clemson University. Matt has held a variety of professional roles with 3M, Dow Chemical, and Merck, and has additional experience as sole proprietor of Edge Biomedical, a biomaterials consulting practice. He maintains current appointments as adjunct professor in the Clemson University Department of Bioengineering and as visiting professor in the Spiro Institute for Entrepreneurial Leadership, where he teaches graduate courses in technology and biomedical entrepreneurship for scientists, engineers and professional business students.
Greg has over 27 years of venture capital investment experience, having played a leadership role in the management of a number of venture capital funds. He currently represents Nexus on the Boards of Aethon, Kiyatec and Zipit Wireless. Greg also represented Nexus as a director of Sabal Medical and Cutanea Life Sciences until he negotiated their sale to a European and Asian acquirer respectively. In the past, he has been an active Board member of both public and private corporations, providing assistance and guidance on issues associated with business strategy, corporate expansion, organizational development, and becoming successful publicly traded companies. Selected investments include Biodel (novel insulin formulation, IPO), PerSeptive Biosystems (protein separation systems, acquired by Perkin Elmer) and Infusion Systems (disposable IV pump, acquired by Baxter).
Prior to joining Nexus, Greg was a general partner of Prince Ventures, a healthcare- focused, venture capital partnership. During the 1980s, Greg was Vice President and Special Limited Partner of the Vista Group where he worked closely with Ed Snape, the leader of Vista’s health care practice, and Bob Fleming, Vista’s IT partner. From 1972 until 1979, Greg was an executive with Baxter Laboratories. His three member team was responsible for bringing CAPD (Continuous Ambulatory Peritoneal Dialysis) into Baxter, where it became the second-most profitable product line in the company, then accounting for approximately 20% of Baxter’s total profits.
Greg received a BS in aerospace and mechanical engineering from Princeton University; an MS in mechanical engineering the Massachusetts Institute of Technology (MIT); and an MS from MIT’s Sloan School of Management.
Christopher is Corporate Vice President of Ortec, Inc., a South Carolina company offering custom manufacturing services for pharmaceutical, medical device and combination products. Prior to joining Ortec, Christopher was with Nalco Company where he held several positions in product marketing, international marketing, and strategic mergers & acquisitions. He holds a bachelors degree in chemistry from Clemson University and an MBA from Wake Forest University.
Marty is currently Vice President, Strategic Investments for SCRA Technology Ventures where he manages the investment review, due diligence, legal and budgetary processes for SCRA’s strategic venture capital investments, Stage 2, and SC Launch, a private SCRA affiliate that provides support and seed capital to early stage technology companies in South Carolina. Marty has completed multiple venture and seed capital investments in the advanced materials, energy, chemical and engineering process, defense/security, information technology and life sciences sectors. Marty currently serves as a director of Integrated Biometrics and KIYATEC and an advisory board member of The Harbor Entrepreneur Center, a business accelerator program that helps startups to build scalable businesses in the Charleston, South Carolina region. In 2013, Marty co-authored the South Carolina Innovation Plan, which proposed recommendations to accelerate the knowledge economy in South Carolina.
Prior to SCRA Technology Ventures, Marty was a Partner and Investment Committee member of Chart Capital Partners, a group of middle-market growth equity and buyout funds. While at Chart Capital Partners, Marty invested over $100 million in growth equity capital in pre-fund and fund investments, with a realized IRR of 25%, and served as a director of Madison/Chart Energy SCS, Wencoast Restaurants, Inc., Infra-Structures, Inc. and PCNY, LLC and a board observer of EOTech, Inc. Marty was also President of Wencoast Restaurants, Inc., where he led a significant restructuring that improved cash flow and positioned the company for a favorable sale. Previously, Marty was a Research Associate in the Automotive Group of Salomon Brothers covering the U.S. automotive manufacturers and original equipment parts suppliers and a Credit Analyst with ABN AMRO Bank N.V. serving Fortune 1000 companies in New England. Marty earned his B.S., with honors, from Babson College.